Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Pharma & Biotech Half-Year Review 2017

Biopharma stages a strong recovery over the first half even as M&A deals disappoint

EvaluatePharma World Preview 2017 EvaluatePharma World Preview 2017 EvaluatePharma World Preview 2017

Download Report

After the first half of 2017 biopharma investors are in a position to be exuberant: the threat of US price controls that have overshadowed the sector for a year have largely disappeared.

The pricing debate has fizzled to proposals for regulatory relief, increased competition and value-based pricing, news of which sent the US biotech index by late June to its highest point since the end of 2015.

Key Highlights

  • Nasdaq Biotechnology Index hit an 18-month high, and healthcare indices in general outperformed wider markets over the first half
  • Initial public offerings of development-stage companies exceeded $1bn in the second quarter, making it the strongest quarter in nearly two years
  • The first half of 2017 generated the lowest number of M&A deals and total transaction value since 2013
  • Venture capital investment looks to be on track to at least match 2016’s total

Press Release

Related Report: EP Vantage Medtech Half-Year Review 2017

Confirm your details on form below to download this report